Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

A Clear Vision: Understanding the Connection Between Ophthalmology & Rheumatic Disease

Jason Liebowitz, MD, FACR  |  August 11, 2022

Meghan Berkenstock, MD, summarized key clinical pearls related to uveitis and rheumatic diseases during a session of the 18th Annual Advances in the Diagnosis & Treatment of the Rheumatic Diseases symposium.

Filed under:ConditionsMeeting Reports Tagged with:Annual Advances in the Diagnosis and Treatment of the Rheumatic DiseaseseyesophthalmologyRheumatic DiseaseRheumatoid Arthritis (RA)SarcoidosisUveitis

JAK Inhibitors: Are All Promises Fulfilled?

Samantha C. Shapiro, MD  |  July 22, 2022

A decade after JAK inhibitors were approved, this EULAR 2022 session looks at whether the drugs have lived up to expectations.

Filed under:Drug UpdatesEULAR/OtherMeeting Reports Tagged with:EULARJAK inhibitorsjakinibsjanus kinase inhibitorRheumatoid Arthritis (RA)

Difficult-to-Treat Lupus: When & How to Use New Therapies

Samantha C. Shapiro, MD  |  July 21, 2022

Clinicians have numerous treatment options for SLE; in a EULAR 2022 session, some of the newer therapies were reviewed.

Filed under:ConditionsEULAR/OtherMeeting ReportsSystemic Lupus Erythematosus Tagged with:belimumabEULARHCQHydroxychloroquine (HCQ)rituximabSLEsystemic lupus erythematosus (SLE)

Biologic or Conventional Therapy for Early RA?

Michele B. Kaufman, PharmD, BCGP  |  July 19, 2022

A study has shown that in untreated patients with early RA, treatment with methotrexate combined with the biologic therapies abatacept or certolizumab-pegol resulted in greater CDAI remission rates than active conventional therapy with prednisolone, sulfasalazine or hydroxychloroquine.

Filed under:Biologics/DMARDsDrug UpdatesEULAR/OtherMeeting Reports Tagged with:Biologicsearly RAEULARRheumatoid Arthritis (RA)

Predicting the Future: Prognostication in Rheumatoid Arthritis

Jason Liebowitz, MD, FACR  |  July 19, 2022

A EULAR 2022 abstract session looked at several studies that seek to increase understanding of RA pathogenesis & identify patients at risk for disease progression.

Filed under:ConditionsEULAR/OtherMeeting ReportsRheumatoid Arthritis Tagged with:anti-advanced glycated end-products (anti-AGE) antibodiesanti-malondialdehyde-acetaldehyde (anti-MAA) antibodiesEULARRheumatoid Arthritis (RA)synovialTenosynovitis

Never Too Late: Late-Breaking Abstracts Create Excitement

Jason Liebowitz, MD, FACR  |  July 15, 2022

EULAR 2022 (VIRTUAL)—The pace of scientific progress in research medicine is incredible and seems to only accelerate with time. Thus, the 2022 Congress of the European Alliance of Associations for Rheumatology (EULAR) session on late-breaking abstracts fittingly captured the excitement and timeliness of a number of research projects that have just recently been completed and…

Filed under:ConditionsEULAR/OtherMeeting Reports Tagged with:baricitinibBimekizumabdeucravacitinibEULARjuvenile idiopathic arthritis (JIA)MethotrexateorelabrutinibPolymyalgia RheumaticaPsoriatic Arthritissarilumabsystemic lupus erythematosus (SLE)

Clinical Guidance & Recommendation Updates for Vasculitis, axSpA & More

Jason Liebowitz, MD, FACR  |  July 15, 2022

In this EULAR 2022 session, new & revised treatment recommendations for ANCA-associated vasculitis, axial spondyloarthritis & rheumatoid arthritis were presented.

Filed under:Axial SpondyloarthritisConditionsEULAR/OtherMeeting ReportsRheumatoid ArthritisVasculitis Tagged with:AAV FocusRheumANCA-Associated Vasculitisanti-neutrophil cytoplasmic antibodies (ANCA)axial spondyloarthritis (SpA)eosinophilic granulomatosis with polyangiitis (EGPA)EULARmicroscopic polyangiitis (MPA)Rheumatoid Arthritis (RA)

FDA Approves Riabni, a Rituxumab Biosimilar, to Treat Patients with RA

Michele B. Kaufman, PharmD, BCGP  |  July 13, 2022

Based on findings from a double-blind, placebo-controlled study evaluating its efficacy and safety, rituximab-arrx has received FDA approval for the treatment of patients with rheumatoid arthritis.

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsFDAFDA approvalRheumatoid Arthritis (RA)RiabniRituxanrituximabrituximab-arrxU.S. Food and Drug Administration (FDA)

A Prescription for Mindfulness

Dana DiRenzo, MD, MHS  |  July 13, 2022

The prescription is a powerful tool for a physician. As rheuma­tologists, we prescribe many things—drugs, physical therapy, durable medical equipment—but what about stress reduction? We are very specific about times of day to take medications and in what manner. Patients ask: With or without food? With other medications? Before or after other prescribed medications? If…

Filed under:AppsEducation & TrainingTechnology Tagged with:meditationmindfulnessself-managementStress

The ACR Responds to Impact of the Dobbs v. Jackson Decision on Rheumatology Patients and Providers

Joseph Cantrell, JD, & Kenneth G. Saag, MD, MSc  |  July 13, 2022

The ACR and a new Access to Reproductive Health Care Task Force are working to ensure patients with rheumatic disease—particularly women—have access to the medications and treatments they need, including methotrexate, and that rheumatology providers are able to maintain trusting relationships with and advise their patients on all matters relevant to the management of their rheumatic diseases.

Filed under:American College of RheumatologyConditionsLegislation & Advocacy Tagged with:Access to careAccess to Reproductive Health Care Task ForceACR advocacyLegalMethotrexatereproductive health

  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 107
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences